By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Current study results on Oncology have been published. According to news reporting originating from Lisbon, Portugal, by NewsRx correspondents, research stated, "The hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT)."
Our news editors obtained a quote from the research from Hospital Center, "The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95% CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95% CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95% CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance."
According to the news editors, the research concluded: "Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT."
For more information on this research see: The HIF1A functional genetic polymorphism at locus+1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. European Journal of Cancer, 2014;50(2):359-365. European Journal of Cancer can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; European Journal of Cancer - www.elsevier.com/wps/product/cws_home/104)
The news editors report that additional information may be obtained by contacting A. Fraga, Cent Lisbon Hosp Center, Dept. of Urol, Lisbon, Portugal. Additional authors for this research include R. Ribeiro, P. Principe, C. Lobato, F. Pina, J. Mauricio, C. Monteiro, H. Sousa, F.C. da Silva, C. Lopes and R. Medeiros (see also Oncology).
Keywords for this news article include: Lisbon, Europe, Therapy, Portugal, Genetics, Oncology, Prostatic Neoplasms, Risk and Prevention, Metastatic Prostate Cancer
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.